Bisphosphonates have been shown to reduce skeletal complications in individuals with bone metastases secondary to a wide range of solid tumors including lung, breast, and prostate cancer [1] . They are widely administered as palliative agents together with chemotherapy, hormonal therapy, or irradiation [2] . In addition, several types of cancer cells including hematologic malignancies respond to bisphosphonates in vitro, with such effects having been attributed, at least in part, to inhibition of the Ras-signaling pathway [3] . We now report an unusual case in which tumors in visceral organs and soft tissues responded markedly to treatment with the bisphosphonate zoledronic acid (ZA) alone, with the performance status of the patient improving in the absence of chemotherapy.
to the left femur, ZA (4 mg/body) was administered i.v. every 4 weeks to reduce bone pain. After 6 months, his general condition was dramatically improved and follow-up FDG-PET revealed decreased uptake of the tracer in metastases not only in bone including the right rib, which was not irradiated, but also in the adrenal glands, abdominal lymph nodes, and s.c. tissue of the right buttock ( Figure 1A As far as we are aware, there have been no other reports of a tumor at a nonskeletal site responding to bisphosphonate treatment alone. ZA was recently shown to have efficacy as a preventive agent for cancer recurrence in premenopausal women with early-stage breast cancer [4] . This previous study suggested that ZA was able to prevent cancer recurrence not only in bone but also in nonskeletal organs including the contralateral breast, lung, and liver. The present case supports the notion that ZA targets not only osteoclasts, a major contributor to the tumor microenvironment in bone, but also tumor cells themselves, as has been shown in preclinical studies [3] . Further clinical evaluation of ZA for treatment of cancer is warranted. 
